This section highlights FDA-related milestones and regulatory updates for drugs developed by ClearPoint Neuro (CLPT).
Over the past two years, ClearPoint Neuro has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
ClearPoint and ClearPoint. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
ClearPoint Prism Neuro Laser Therapy System FDA Regulatory Events
ClearPoint Prism Neuro Laser Therapy System is a drug developed by ClearPoint Neuro for the following indication: Brain Tumor Laser Therapy.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- ClearPoint Prism Neuro Laser Therapy System
- Announced Date:
- October 7, 2025
- Indication:
- Brain Tumor Laser Therapy
Announcement
ClearPoint Neuro, Inc announced results from a Phase I-II clinical study at Skåne University Hospital in Lund, Sweden evaluating the ClearPoint Prism Neuro Laser Therapy System's safety, feasibility, and efficacy..
AI Summary
ClearPoint Neuro, Inc. shared Phase I-II study results from Skåne University Hospital in Lund, Sweden. This trial tested the ClearPoint Prism Neuro Laser Therapy System for safety, feasibility, and effectiveness in 14 patients with primary or recurrent glioblastoma or grade 4 astrocytoma.
The findings showed improved survival compared to matched open‐surgery controls, with no device‐related events or complications. The workflow proved safe, feasible, and reproducible, and the median time to ablate each tumor was just 6.5 minutes.
Chris Osswald, PhD, said these results show potential for minimally invasive neuro‐oncology treatment. He added that the system’s fast, simple, and predictable workflow can improve patient care and support future cell and gene therapy applications.
The ClearPoint Prism Neuro Laser Therapy System will be featured at the 75th Annual Congress of Neurological Surgeons in Los Angeles on October 13–15, 2025.
Read Announcement
ClearPoint Neuro Navigation software. FDA Regulatory Events
ClearPoint Neuro Navigation software. is a drug developed by ClearPoint Neuro for the following indication: Software Version 2.1.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- ClearPoint Neuro Navigation software.
- Announced Date:
- June 20, 2024
- Indication:
- Software Version 2.1
Announcement
ClearPoint Neuro, congratulates its partner Aspen Neuroscience, Inc. on use of the ClearPoint Neuro Navigation System to transplant dopaminergic neuron precursor cells (DANPCs) for all enrolled patients with Parkinson's Disease (PD) in its recently launched ASPIRO Phase 1/2a clinical trial.
AI Summary
ClearPoint Neuro recently congratulated its partner, Aspen Neuroscience, Inc., for successfully using the ClearPoint Neuro Navigation System in its ASPIRO Phase 1/2a clinical trial for Parkinson’s Disease. In this trial, all enrolled patients receive a transplant of dopaminergic neuron precursor cells (DANPCs) into the putamen, a key brain structure affected by the disease. This innovative approach uses MRI guidance, the SmartFlow® Cannula, and the Aspen Metered Delivery Syringe (AMDS) during a single surgical procedure.
The streamlined process, developed under the expertise of leading neurosurgeon Dr. Paul Larson, aims to reduce surgical variability and boost safety, which is essential for assessing both safety and tolerability of the therapy. This milestone reflects a promising step forward in regenerative treatment options for patients with moderate to severe Parkinson’s Disease.
Read Announcement
